ImmunityBio, Inc.
IBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.41 | -0.29 | -0.13 |
| FCF Yield | -22.30% | -15.56% | -20.50% | -13.01% |
| EV / EBITDA | -8.11 | -6.30 | -7.52 | -8.83 |
| Quality | ||||
| ROIC | -102.60% | -80.24% | -118.66% | -82.13% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.95 | 0.63 | 0.81 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 294.59% | -12.67% | -26.52% | 179.01% |
| Free Cash Flow Growth | -0.20% | 4.41% | -34.97% | -77.62% |
| Safety | ||||
| Net Debt / EBITDA | -1.36 | -0.96 | -1.76 | -1.45 |
| Interest Coverage | -2.61 | -4.18 | -7.45 | -22.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 65.67 | 1,859.04 | 2,874.38 | 520.93 |